Forgot Password?
Return to Course Listing

CME: Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 and other recent society meetings

ACCREDITATION EXPIRED: February 03, 2025

Activity Description / Statement of Need:

In this online, self-learning activity:

Cancer of the liver is one of the leading causes of cancer-related deaths and one of the more common types of cancer worldwide, with an incidence of over 41,000 in the U.S. and an annual mortality rate of over 29,000 new cases each year. Of all the primary liver cancers, hepatocellular carcinoma (HCC) is the most common form, representing 80%, and its incidence has risen threefold in the U.S. over the past 40 years. HCC is most often diagnosed in late stages of disease and carries a grave prognosis with a five-year survival rate of three percent in patients with metastases, suggesting opportunity for improvement and potential gaps in care.

Target Audience:

HCPs including: medical oncologists, gastroenterologists, and hepatologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with advanced or unresectable HCC.


Commercial Support Disclosure: This program is supported by an educational grant from Merck.

This activity is free of charge.


Release Date: February 03, 2024 -- Expiration Date: February 03, 2025

Faculty: Tanios Bekaii‐Saab, MD

Agenda

  • Faculty Member Introduction and Disclosures
  • Overview of HCC
  • Summary of current treatment landscape
  • Summary of emerging treatment landscape including major findings from ESMO 2023

and other recent society meetings

  • Clinical applicability
  • Concluding Remarks

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the global burden and risk factors for the development of HCC.
  • Identify the emerging role of immunotherapy combinations in the treatment of HCC, and apply that information to a patient case.
  • Describe the intersectionality of systemic and locoregional modalities and their roles in the treatment of earlier stage HCC.

Accreditation

ACCME Activity #202614064

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Tanios S. Bekaii‐Saab, MD, Professor of Medicine, Mayo Clinic Collegeof Medicine and Science, has received financial compensation from Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine, Sanofi, Glaxo SmithKlin, Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma for consulting and/or advisory board activities.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Taking the ‘pep’ out of H. pylori infection: updates in practice and treatment optimization

Acute hepatic porphyria: optimizing pharmacotherapeutic management strategies

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)